Extended adjuvant endocrine therapy of early breast cancer

References

• Imaginis. Breast cancer: statistics on incidence, survival, and screening. Available at: www.imaginis.com/breasthealth/statistics.asp. [Accessed August 24, 2004]
   Google Scholar
• American Cancer Society. Cancer facts and figures 2004. Available at: http://www.cancer.org. [Accessed July 20, 2004]
   Google Scholar
• Dowsett M. Rationale for the endocrine treatment of breast cancer. In: Dowsett M (Ed). Endocrine Aspects of Breast Cancer. Carnforth, England: Parthenon; 1992:11–24
   Google Scholar
• Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276–85
   PubMed Web of Science ®Google Scholar
• Miller WR. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol 2003;30 (Suppl 14):3–11
   PubMedGoogle Scholar
• National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. Version 1.2005. Available at www.nccn.org/physician_gls/f_guidelines.html [Accessed 12 March 2005]
   Google Scholar
• Fisher B, Jeong JH, Bryant J, et al. Treatment of lymphnode-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004;364: 858–68
   PubMed Web of Science ®Google Scholar
• Fisher B, Osborne CK, Margolese RG, Bloomer WD. Neoplasms of the breast. In: Holland JF, Frei E III, Bast RC Jr, Kufe D, Morton D (Eds). Cancer Medicine, 4th edn. Baltimore, MD: Williams & Wilkins; 1997, pp. 2349–429
   Google Scholar
• Winer EP, Morrow M, Osborne CK, Harris JR. Malignant tumors of the breast. In: DeVita VT Jr, Hellman S, Rosenberg SA (Eds). Cancer: Principles and Practice of Oncology, 6th edn. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001, pp. 1651–717
   Google Scholar
• Santen RJ, Harvey HA. Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer 1999;6:75–92
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen-positive tumors. J Natl Cancer Inst 1996;88:1529–42
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684–90
   PubMed Web of Science ®Google Scholar
• Goss PE. Preliminary data from ongoing adjuvant aromatase inhibitor trials. Clin Cancer Res 2001\(Suppl 7):4397s–4401s
   Google Scholar
• Berstein LM, Wang J-P, Zheng H, et al. Long-term exposure to tamoxifen induces hypersensitivity to estradiol. Clin Cancer Res 2004;10:1530–34
   Google Scholar
• Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738–46
   Google Scholar
• Chia SK, Speers CH, Bryce CJ, et al. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 2004;22:1630–37
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451–67
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Kau S-W, Buzdar AU, et al. What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? Proc Am Soc Clin Oncol 2004;23:23. Abstract 585; and poster presentation at the Fortieth Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 25–28, 2004
   Google Scholar
• Stein RC, Dowsett M, Hedley A, Gazet J-C, et al. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 1990;62: 679–83
   Google Scholar
• Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20:751–7
   PubMed Web of Science ®Google Scholar
• Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453–61
   PubMed Web of Science ®Google Scholar
• Buzdar A, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998;83:1142–52
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000;18:1399–1411
   PubMed Web of Science ®Google Scholar
• Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomized trial comparing 2.5 mg daily, 0.5 mg daily, and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 1998;9: 639–45
   Google Scholar
• Rose C. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. Am J Clin Oncol 2003;26:S9–S16
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596–606
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101–9
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: results of two randomized trials designed for combined analysis. Cancer 2001;92:2247–58
   PubMed Web of Science ®Google Scholar
• Paridaens R, Therasse P, Dirix L, et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) – A randomized phase III trial of the EORTC Breast Group. Proc Am Soc Clin Oncol 2004;23:6. Abstract 515; and oral presentation at the Fortieth Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5–8, 2004
   Google Scholar
• Mouridsen HT, Rose C, Brodie AH, Smith IE. Challenges in the endocrine management of breast cancer. Breast 2003;12 (Suppl 2):S2–S19
   PubMedGoogle Scholar
• Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131–9
   PubMed Web of Science ®Google Scholar
• Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802–10
   PubMed Web of Science ®Google Scholar
• Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793–802
   PubMed Web of Science ®Google Scholar
• Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527–32
   PubMed Web of Science ®Google Scholar
• Smith I, Dowsett M. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer Res Treat 2003;82\(Suppl 1):S6, Abstract 1; and oral presentation at the Twenty-Sixth Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 3–6, 2003
   Google Scholar
• Cataliotti L, Buzdar A, Noguchi S, Bines J. Efficacy of preoperative Arimidex (anastrozole) compared with tamoxifen (PROACT) as neoadjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer. Eur J Cancer 2004\(Suppl 2):69, Abstract 46
   Google Scholar
• Howell A, on behalf of the ATAC Trialists’ Group. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer – updated efficacy results based on a median follow-up of 5 years. Breast Cancer Res Treat 2004;88\(Suppl 1):S7, Abstract 1; and oral presentation at the Twenty-Seventh Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8–11, 2004
   Google Scholar
• Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:60–62
   PubMed Web of Science ®Google Scholar
• Howell A. Effect of anastrozole on bone mineral density: 2-year results of the ‘arimidex’ (anastrozole), tamoxifen, alone or in combination (ATAC) trial. Breast Cancer Res Treat 2003;82\(Suppl 1):S27, Abstract 129; and oral presentation at the Twenty-Sixth Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 3–6, 2003
   Google Scholar
• Thürlimann B. Letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer: First results of IBCSG 18–98/BIG 1–98. Presentation at Ninth International Conference on Primary Therapy of Early Breast Cancer, St. Gallen, Switzerland, January 26, 2005 . Available at: http://www.ibcsg.org/index.shtm [Accessed January 31, 2005]
   Google Scholar
• Coombes RC, Hall E, Snowdon CF, Bliss JM. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen – updated survival analysis. Breast Cancer Res Treat 2004;88\(Suppl 1):S7, Abstract 3; and oral presentation at the Twenty-Seventh Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8–11, 2004
   Google Scholar
• Goss PE, Qi S, Josse RG, et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 2004;34:84–392
   Google Scholar
• Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 2005;23:5138–47
   PubMed Web of Science ®Google Scholar
• Boccardo FM, Rubagotti A, Puntoni M, et al. Switching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trial. J Clin Oncol 2005;23(16S):10s, Abstract 526; and poster presentation at the Forty-First Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13–17, 2005
   Google Scholar
• Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455–62
   PubMed Web of Science ®Google Scholar
• Goss PE. Randomized placebo-controlled trial of letrozole in postmenopausal women with early breast cancer completing five years of tamoxifen. Oral presentation at the Twenty-Sixth Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 5, 2003
   Google Scholar
• Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262–71
   PubMed Web of Science ®Google Scholar
• Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole vs placebo on bone mineral density in women completing ³ 5 years of adjuvant tamoxifen: NCIC CTG MA.17B. Breast Cancer Res Treat. 2004;88\(Suppl 1):S36, Abstract 404; and poster presentation at the Twenty-Seventh Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8–11, 2004
   Google Scholar
• Whelan T, Goss P, Ingle J, et al. Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. Proc Am Soc Clin Oncol 2004;23:6, Abstract 517; and oral presentation at the Fortieth Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5–8, 2004
   Google Scholar
• Jakesz R, Samonigg H, Greil R, et al. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol 2005;23(16S):10s, Abstract 527; and poster presentation at the Forty-First Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13–17, 2005
   Google Scholar
• Ligibel JA, Winer EP. Clinical differences among the aromatase inhibitors. Clin Cancer Res 2003;9(Suppl):473s–479s
   Google Scholar
• Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619–29
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357–65
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Glick JH, Gelber RD, et al. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol 2005;16:1569–83
   PubMed Web of Science ®Google Scholar
• Rea D. Phase III randomized study of adjuvant exemestane versus adjuvant tamoxifen in postmenopausal women with early breast cancer. Protocol CRC-TU-TEAM. Available at: www. cancer.gov/clinicaltrials [Accessed January 14, 2004]
   Google Scholar
• Thürlimann B, Mauriac L, Mouridsen H. Phase III randomized study of adjuvant letrozole versus tamoxifen in postmenopausal women with operable, hormone receptor-positive breast cancer. Protocol IBCSG-1–98. Available at: www.cancer.gov/clinicaltrials [Accessed January 14, 2004]
   Google Scholar
• Bryant J, Wolmark N. Letrozole after tamoxifen for breast cancer – what is the price of success? N Engl J Med 2003;349:1855–7
   PubMed Web of Science ®Google Scholar
• Mamounas T. Phase III randomized study of exemestane in postmenopausal women with resected stage I, II, or IIIA breast cancer who have completed five years of tamoxifen. Protocol NSABP-B-33. Available at: www.cancer.gov/clinicaltrials [Accessed January 14, 2004]
   Google Scholar
• Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042–57
   PubMed Web of Science ®Google Scholar
• Gnant M, Hausmaninger H, Samonigg H, et al. Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: results of a randomized multicenter trial. Breast Cancer Res Treat 2002;76\(Suppl 1):S31, Abstract 12
   Google Scholar
• Gnant M, Jakesz R, Mlineritsch B, et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen – bone density subprotocol results of a randomized multicenter trial (ABCSG-12). Breast Cancer Res Treat. 2004;88\(Suppl 1):S8-S9, Abstract 6; and oral presentation at the Twenty-Seventh Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8–11, 2004
   Google Scholar
• Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial – the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150–57
   PubMed Web of Science ®Google Scholar
• Brufsky A, Harker G, Beck T, et al. Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): preliminary results of the Z-FAST trial. Poster presentation at the Twenty-Seventh Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8–11, 2004
   Google Scholar